{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:23:07Z","timestamp":1772119387559,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00432-021-03846-6","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T06:07:10Z","timestamp":1637820430000},"page":"2959-2969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adjuvant chemotherapy following combined induction chemotherapy and concurrent chemoradiotherapy improves survival in N2\u20133-positive nasopharyngeal carcinoma patients"],"prefix":"10.1007","volume":"148","author":[{"given":"Hao-Yun","family":"Tao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai-Xian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Peng","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Wei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1934-0772","authenticated-orcid":false,"given":"Rong-Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"issue":"1","key":"3846_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0973-1482.48763","volume":"5","author":"S Afqir","year":"2009","unstructured":"Afqir S, Ismaili N, Errihani H (2009) Concurrent chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: current status. J Cancer Res Ther 5(1):3\u20137. https:\/\/doi.org\/10.4103\/0973-1482.48763","journal-title":"J Cancer Res Ther"},{"issue":"4","key":"3846_CR2","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/jco.1998.16.4.1310","volume":"16","author":"M Al-Sarraf","year":"1998","unstructured":"Al-Sarraf M, LeBlanc M, Giri PG et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16(4):1310\u20131317. https:\/\/doi.org\/10.1200\/jco.1998.16.4.1310","journal-title":"J Clin Oncol"},{"issue":"16","key":"3846_CR3","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/sim.5705","volume":"32","author":"PC Austin","year":"2013","unstructured":"Austin PC (2013) The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 32(16):2837\u20132849. https:\/\/doi.org\/10.1002\/sim.5705","journal-title":"Stat Med"},{"issue":"7","key":"3846_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jnci\/dji084","volume":"97","author":"AT Chan","year":"2005","unstructured":"Chan AT, Leung SF, Ngan RK et al (2005) Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97(7):536\u2013539. https:\/\/doi.org\/10.1093\/jnci\/dji084","journal-title":"J Natl Cancer Inst"},{"key":"3846_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1200\/JCO.2018.77.7847","volume":"15","author":"ATC Chan","year":"2018","unstructured":"Chan ATC, Hui EP, Ngan RKC et al (2018) Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol 15:10. https:\/\/doi.org\/10.1200\/JCO.2018.77.7847","journal-title":"J Clin Oncol"},{"issue":"23","key":"3846_CR6","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/jnci\/djr432","volume":"103","author":"QY Chen","year":"2011","unstructured":"Chen QY, Wen YF, Guo L et al (2011) Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 103(23):1761\u20131770. https:\/\/doi.org\/10.1093\/jnci\/djr432","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"3846_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/s1470-2045(11)70320-5","volume":"13","author":"L Chen","year":"2012","unstructured":"Chen L, Hu CS, Chen XZ et al (2012) Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 13(2):163\u2013171. https:\/\/doi.org\/10.1016\/s1470-2045(11)70320-5","journal-title":"Lancet Oncol"},{"key":"3846_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2017.01.002","volume":"75","author":"L Chen","year":"2017","unstructured":"Chen L, Hu CS, Chen XZ et al (2017) Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer 75:150\u2013158. https:\/\/doi.org\/10.1016\/j.ejca.2017.01.002","journal-title":"Eur J Cancer"},{"issue":"8","key":"3846_CR9","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-17-2656","volume":"24","author":"YP Chen","year":"2018","unstructured":"Chen YP, Tang LL, Yang Q et al (2018) Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res 24(8):1824\u20131833. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2656","journal-title":"Clin Cancer Res"},{"issue":"10192","key":"3846_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT et al (2019) Nasopharyngeal carcinoma. The Lancet 394(10192):64\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(19)30956-0","journal-title":"The Lancet"},{"issue":"7","key":"3846_CR11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","volume":"39","author":"Y-P Chen","year":"2021","unstructured":"Chen Y-P, IsmailaChua NMLK et al (2021a) Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline. J Clin Oncol 39(7):840\u2013859. https:\/\/doi.org\/10.1200\/JCO.20.03237","journal-title":"J Clin Oncol"},{"issue":"10297","key":"3846_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0140-6736(21)01123-5","volume":"398","author":"YP Chen","year":"2021","unstructured":"Chen YP, Liu X, Zhou Q et al (2021b) Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. The Lancet 398(10297):303\u2013313. https:\/\/doi.org\/10.1016\/s0140-6736(21)01123-5","journal-title":"The Lancet"},{"issue":"1","key":"3846_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/jrr\/rrs071","volume":"54","author":"Y Goto","year":"2013","unstructured":"Goto Y, Kodaira T, Fuwa N et al (2013) Alternating chemoradiotherapy in patients with nasopharyngeal cancer: prognostic factors and proposal for individualization of therapy. J Radiat Res 54(1):98\u2013107. https:\/\/doi.org\/10.1093\/jrr\/rrs071","journal-title":"J Radiat Res"},{"issue":"5","key":"3846_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.21037\/atm.2019.02.15","volume":"7","author":"Y He","year":"2019","unstructured":"He Y, Guo T, Wang J et al (2019) Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma? Ann Transl Med 7(5):104. https:\/\/doi.org\/10.21037\/atm.2019.02.15","journal-title":"Ann Transl Med"},{"issue":"2","key":"3846_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","volume":"27","author":"EP Hui","year":"2009","unstructured":"Hui EP, Ma BB, Leung SF et al (2009) Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27(2):242\u2013249. https:\/\/doi.org\/10.1200\/JCO.2008.18.1545","journal-title":"J Clin Oncol"},{"issue":"7","key":"3846_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1089\/thy.2011.0380","volume":"22","author":"E Kim","year":"2012","unstructured":"Kim E, Matsuse M, Saenko V et al (2012) Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in anaplastic thyroid carcinoma cells. Thyroid 22(7):717\u2013724. https:\/\/doi.org\/10.1089\/thy.2011.0380","journal-title":"Thyroid"},{"issue":"6","key":"3846_CR17","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jtcvs.2004.12.050","volume":"129","author":"KF Kwong","year":"2005","unstructured":"Kwong KF, Edelman MJ et al (2005) High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg 129(6):1250\u20131257. https:\/\/doi.org\/10.1016\/j.jtcvs.2004.12.050","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"3846_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ijc.32099","volume":"145","author":"WF Li","year":"2019","unstructured":"Li WF, Chen NY, Zhang N et al (2019) Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial. Int J Cancer 145(1):295\u2013305. https:\/\/doi.org\/10.1002\/ijc.32099","journal-title":"Int J Cancer"},{"issue":"4","key":"3846_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2003.06.158","volume":"21","author":"JC Lin","year":"2003","unstructured":"Lin JC, Jan JS, Hsu CY et al (2003) Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21(4):631\u2013637. https:\/\/doi.org\/10.1200\/JCO.2003.06.158","journal-title":"J Clin Oncol"},{"key":"3846_CR20","unstructured":"National Cancer Institute-Common Toxicity Criteria Adverse Events Versions 4. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010\u201306 14_QuickReference_8.5x11.pdf."},{"key":"3846_CR21","unstructured":"National Comprehensive Cancer Network (2021) NCCN clinical practice guidelines in oncology: head and neck cancers. Version 2.  https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf. Accessed Apr 2021"},{"issue":"5","key":"3846_CR22","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","volume":"35","author":"L Ribassin-Majed","year":"2017","unstructured":"Ribassin-Majed L, Marguet S, Lee AWM et al (2017) What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 35(5):498\u2013505. https:\/\/doi.org\/10.1200\/JCO.2016.67.4119","journal-title":"J Clin Oncol"},{"issue":"3","key":"3846_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1200\/JCO.2006.08.2826","volume":"25","author":"VW Rusch","year":"2007","unstructured":"Rusch VW, Giroux DJ, Kraut MJ et al (2007) Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 25(3):313\u2013318. https:\/\/doi.org\/10.1200\/JCO.2006.08.2826","journal-title":"J Clin Oncol"},{"issue":"4","key":"3846_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3892\/ol.2013.1498","volume":"6","author":"L Song","year":"2013","unstructured":"Song L, Liu H, Ma L et al (2013) Inhibition of autophagy by 3-MA enhances endoplasmic reticulum stress-induced apoptosis in human nasopharyngeal carcinoma cells. Oncol Lett 6(4):1031\u20131038. https:\/\/doi.org\/10.3892\/ol.2013.1498","journal-title":"Oncol Lett"},{"issue":"3","key":"3846_CR25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.radonc.2013.10.020","volume":"110","author":"X Sun","year":"2014","unstructured":"Sun X, Su S, Chen C et al (2014) Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 110(3):398\u2013403. https:\/\/doi.org\/10.1016\/j.radonc.2013.10.020","journal-title":"Radiother Oncol"},{"issue":"11","key":"3846_CR26","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/s1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY et al (2016) Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 17(11):1509\u20131520. https:\/\/doi.org\/10.1016\/s1470-2045(16)30410-7","journal-title":"Lancet Oncol"},{"issue":"23","key":"3846_CR27","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1200\/jco.2012.46.0816","volume":"31","author":"LQ Tang","year":"2013","unstructured":"Tang LQ, Chen QY, Fan W et al (2013) Prospective study of tailoring whole-body dual-modality [18F]Fluorodeoxyglucose positron emission tomography\/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 31(23):2861\u20132869. https:\/\/doi.org\/10.1200\/jco.2012.46.0816","journal-title":"J Clin Oncol"},{"issue":"2","key":"3846_CR28","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/jso.26305","volume":"123","author":"AA White","year":"2021","unstructured":"White AA, Lee DN, Mazzola E et al (2021) Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer. J Surg Oncol 123(2):579\u2013586. https:\/\/doi.org\/10.1002\/jso.26305","journal-title":"J Surg Oncol"},{"issue":"4","key":"3846_CR29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.7150\/ijbs.12937","volume":"12","author":"X Zhang","year":"2016","unstructured":"Zhang X, Du L, Zhao F et al (2016) A phase II clinical trial of concurrent helical tomotherapy plus cetuximab followed by adjuvant chemotherapy with cisplatin and docetaxel for locally advanced nasopharyngeal carcinoma. Int J Biol Sci 12(4):446\u2013453. https:\/\/doi.org\/10.7150\/ijbs.12937","journal-title":"Int J Biol Sci"},{"issue":"12","key":"3846_CR30","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ et al (2019) Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 381(12):1124\u20131135. https:\/\/doi.org\/10.1056\/NEJMoa1905287","journal-title":"N Engl J Med"},{"key":"3846_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.619625","volume":"10","author":"R Zou","year":"2020","unstructured":"Zou R, Yuan JJ, Li Q et al (2020) The clinical outcomes and toxicities of induction chemotherapy followed by concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol 10:619625. https:\/\/doi.org\/10.3389\/fonc.2020.619625","journal-title":"Front Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03846-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03846-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03846-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T07:35:18Z","timestamp":1663918518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03846-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["3846"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03846-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-848732\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"27 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was approved by the Institutional Review Board (IRB) of the Affiliated Cancer Hospital & Institute of Guangzhou Medical University. Patients were required to provide written informed consent before enrolling in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}